Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives

Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives

The advancement of immune-therapeutics in cancer treatment has proven to be promising in various malignant diseases. However, in castration resistant prostate cancer (mCRPC) major Phase III trials have been unexpectedly disappointing. To contribute to a broader understanding of the role and use of i...

Full description

Bibliographic Details
Main Authors: H. Taghizadeh, M. Marhold, E. Tomasich, S. Udovica, A. Merchant, M. Krainer
Format: Article
Language:English
Published: Taylor & Francis Group 2019-11-01
Series:OncoImmunology
Subjects:
mcrpc
immunotherapy
vaccines
checkpoint inhibitors
t lymphocytes
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1644109

Internet

http://dx.doi.org/10.1080/2162402X.2019.1644109

Similar Items